Found Weight Loss Program review: is it worth it?

What is Found and how does it work?

Found (operated by Found Health, Inc.) is a direct-to-consumer "metabolic care" company that was incubated at the San Francisco venture studio Atomic around 2020 and is led by CEO Sarah Jones Simmer, a former Bumble executive. It has raised well over $100 million from investors including GV (Google Ventures), Atomic, and WestCap, and markets itself as one of the larger online weight-loss clinics in the United States.

Structurally, Found is a telehealth platform, not a pharmacy or a drug maker. The model is consistent across the company's materials and third-party reviews:

1. Online assessment. You complete a detailed health questionnaire covering weight history, medical conditions, medications, and goals.
2. Clinician review. A licensed clinician reviews your assessment to determine eligibility and, if appropriate, selects and prescribes a medication. Found markets a proprietary "MetabolicPrint" personalization framework it says guides which medication and approach fit each member.
3. Medication. Depending on the plan and your clinical profile, the prescribed drug is dispensed through Found's partner pharmacies (including compounded GLP-1s) or written for you to fill elsewhere (for branded GLP-1s).
4. Ongoing support. The membership includes monthly clinical check-ins with dose adjustments, lifestyle and nutrition guidance, an in-app AI assistant ("Found Assistant"), and access to a member community.

The single most important structural fact: Found's value is in access and coaching, while the medication is what actually drives weight loss. What medication you end up on — and whether it is an FDA-approved branded drug, a generic oral medication, or a non-FDA-approved compounded product — matters far more to your results and safety than the app experience.

What medications does Found prescribe?

This is where Found differs from a single-drug program, and it cuts both ways. Found's clinicians can prescribe across a wide spectrum:

• Branded, FDA-approved GLP-1 / GIP medications: semaglutide (Wegovy for weight loss; Ozempic, the diabetes version) and tirzepatide (Zepbound for weight loss; Mounjaro for diabetes). These carry the strongest evidence (see below). For these, Found generally writes the prescription and the drug's cost is billed separately — through insurance if covered, or cash if not.
• Compounded semaglutide and tirzepatide: lower-cost versions made by compounding pharmacies, sometimes included in the membership price.
• Older, generic prescription options: metformin, the naltrexone/bupropion combination (Contrave), and others, which are inexpensive but substantially less potent for weight loss.
• Oral GLP-1 options such as oral semaglutide. (In December 2025 the FDA approved an oral semaglutide 25 mg pill, marketed as oral Wegovy, for chronic weight management; lower-dose oral semaglutide, sold as Rybelsus, remains indicated for type 2 diabetes rather than weight loss.)

The breadth is genuinely useful for people who can't access or afford branded GLP-1s. But it also means the label "Found weight loss" can describe wildly different treatments. Being put on metformin is not the same intervention as being put on Zepbound, and the difference in expected results is large.

The compounded-medication caveat is serious

Found offers compounded semaglutide and tirzepatide, and the company's own disclosures acknowledge that compounded GLP-1s are not FDA-approved and not evaluated by the FDA for safety, efficacy, or quality. This is an industry-wide issue, not unique to Found, but it deserves emphasis. After the FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in February 2025, the regulatory window that allowed mass-scale compounding of these drugs largely closed, and the FDA has repeatedly warned about the risks of unapproved compounded GLP-1 products, including dosing errors and quality concerns (FDA). In 2025 the FDA also issued warning letters to numerous telehealth companies over misleading compounded GLP-1 marketing. If Found steers you toward a compounded product, you are accepting a meaningful step down in regulatory protection compared with a branded, FDA-approved drug — and you should ask explicitly which you are getting.

How well do the medications actually work?

Because Found is a delivery vehicle for several different drugs, "does Found work?" really means "how well does the specific drug you're prescribed work?" Here is the honest tier list, grounded in published trials.

The branded GLP-1 / GIP drugs are the most effective — and best validated

• Semaglutide 2.4 mg (Wegovy): In the pivotal STEP 1 trial, adults with obesity lost a mean of about 14.9% of body weight over 68 weeks versus roughly 2.4% on placebo (NEJM 2021; PMID 33567185).
• Tirzepatide (Zepbound): In SURMOUNT-1, participants without diabetes lost a mean of about 15%, 19.5%, and 20.9% of body weight at the 5, 10, and 15 mg doses respectively over 72 weeks (NEJM 2022; PMID 35658024).

These are among the most effective non-surgical obesity treatments ever studied. If Found prescribes one of these, your expected results are anchored to this strong evidence base.

The older oral options are real but far weaker

• Naltrexone/bupropion (Contrave): In the Phase 3 COR program, the combination produced meaningfully more weight loss than placebo — on the order of roughly 5–6% of body weight versus about 1–2% on placebo over a year (FDA label; COR trials). That is a fraction of GLP-1 results.
• Metformin: Not FDA-approved for weight loss. The weight effect is modest, commonly described as a few percent of body weight, and the drug is mainly a diabetes medication (NIH/NIDDK; the Diabetes Prevention Program showed metformin produced modest weight loss and diabetes-prevention benefit, well below intensive lifestyle change).
• Oral semaglutide: As of December 2025 there is an FDA-approved oral semaglutide 25 mg pill (oral Wegovy) for chronic weight management, supported by the OASIS 4 trial (about 13.6% mean weight loss at 64 weeks). Lower-dose oral semaglutide sold as Rybelsus is approved for type 2 diabetes, not weight loss, so its use for weight loss is off-label; the longest and largest weight-loss evidence base remains the injectable 2.4 mg formulation.

So if you are placed on metformin or Contrave because a GLP-1 isn't accessible or affordable, your realistic expectations should be much more modest than the headline GLP-1 figures Found's marketing tends to evoke.

Found's own program results

Found has cited member outcomes from a peer-reviewed retrospective analysis of its members (published in early 2025): a mean weight loss of roughly 8% at 12 months across the studied population, rising to about 10% among members who stayed active in the app at least weekly over those 12 months (with reported 6-month figures closer to 5–6%). These figures are observational and company-affiliated, drawn from a self-selected, paying, motivated population, and they are not independent randomized trials. They blend members on potent GLP-1s with members on weaker drugs, so they should be read as real-world data, not as proof the program itself outperforms simply getting the same medication elsewhere.

What does Found cost and what do you actually pay?

Found uses a monthly membership model, and pricing has shifted frequently with promotions. Recent advertised pricing has ranged from introductory rates as low as roughly $49/month up to about $99–$149/month for the program subscription, sometimes with a free first month on multi-month "Kickstart" plans. Plans are typically HSA/FSA eligible.

The critical thing to understand is what that fee does and does not include:

• The membership covers the clinical care, coaching, app, and support — and, in some plans, the cost of a compounded medication.
• Branded GLP-1 medications are billed separately. If your insurance covers them, you pay the membership plus a copay (Found cites copays around $30 for many insured members, though this varies widely by plan and deductible). If insurance does not cover GLP-1s for weight loss — which is extremely common — you pay cash for an expensive brand-name drug on top of the membership.

This produces two very different financial outcomes:

• Best case: Insurance covers your branded GLP-1, and you pay only Found's membership plus a modest copay. The all-in cost is reasonable.
• Common case: No GLP-1 coverage, so you either pay Found's membership plus full cash price for a branded drug (often several hundred dollars a month or more), or you accept a lower-cost compounded product with its FDA caveats, or you settle for a cheap-but-weak generic like metformin. Reported all-in monthly costs for members on medication through Found commonly land in the rough range of $150–$350+, depending heavily on the drug.

Read the offer terms carefully: promotional first-month pricing converts to standard monthly billing, and subscriptions are recurring.

Is Found legitimate and safe?

The core model is legitimate. Found uses real licensed clinicians, is a venture-backed company operating openly, and its branded-GLP-1 and generic pathways involve FDA-approved drugs with established safety profiles. That is meaningfully more transparent than anonymous gray-market sellers.

The legitimacy concerns are specific and worth weighing:

• The compounded-drug pathway carries the regulatory and quality uncertainty described above. This is the most important safety asterisk.
• Telehealth prescribing limits. A brief online assessment is not the same as longitudinal in-person care. People with complex medical histories may be better served by a physician who can examine them and order labs directly.
• Service and billing complaints. Like many fast-growing telehealth weight-loss companies, Found has accumulated consumer complaints around billing, cancellation friction, medication delays, and difficulty reaching support. The recurring-subscription structure means you should confirm cancellation terms before enrolling.

Standard GLP-1 safety considerations apply to the branded and compounded GLP-1 pathways (these come from FDA labeling, not from Found):

• Common side effects: nausea, vomiting, diarrhea, constipation, and abdominal discomfort, usually worst during dose escalation.
• Boxed warning: semaglutide and tirzepatide carry an FDA boxed warning for thyroid C-cell tumor risk based on rodent studies; they are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Other labeled risks: pancreatitis, gallbladder disease, and acute kidney injury from dehydration due to vomiting; caution with insulin/sulfonylureas (hypoglycemia).
• Not for use in pregnancy. Contrave separately carries warnings around bupropion (seizure risk, neuropsychiatric effects) and naltrexone (opioid-use contraindications).

Who is Found best for — and who should skip it?

Found may be a reasonable fit if you:

• Want a single platform that can flexibly match you to a range of medication options, including affordable generics if a GLP-1 isn't accessible.
• Have insurance that covers branded GLP-1s, so the membership plus copay is your main cost.
• Value app-based coaching, structured check-ins, and a community, and will actually use them.
• Are clinically appropriate for medication-assisted weight loss and don't have contraindications.

You should probably skip Found, or proceed cautiously, if you:

• Specifically want a branded, FDA-approved GLP-1 and have no insurance coverage — you may pay a membership fee on top of full cash drug prices, and a manufacturer direct option or a transparent cash-pay telehealth provider may be cheaper.
• Are uncomfortable being routed to a compounded, non-FDA-approved product to hit a lower price.
• Have contraindications to the relevant drugs (medullary thyroid cancer/MEN 2 history, pancreatitis, pregnancy, or seizure/opioid issues for Contrave).
• Have a complex medical history better managed by in-person care.
• Dislike recurring subscriptions or have seen the billing/cancellation complaints and want to avoid that friction.

How does Found compare to alternatives?

The online weight-loss market has crowded fast, and Found sits in a specific niche:

• Insurance-billed coaching programs (Calibrate, WeightWatchers Clinic): Similar premise — medication plus behavioral support, drug billed through insurance. Calibrate leans into intensive 1:1 coaching and metabolic-marker tracking; Found leans into medication breadth and an AI-plus-community model at generally lower membership prices.
• Cash-pay branded telehealth and manufacturer direct (Ro, Sesame, LillyDirect, NovoCare): Often the most transparent on total cost and the cleanest path to a genuine branded drug if you're paying cash, though typically lighter on coaching.
• Compounded-GLP-1 platforms (Hims, others): Compete mainly on low sticker price for compounded products, with the same FDA caveats Found's compounded option carries.
• Your own PCP or an obesity-medicine clinic: Usually the lowest-cost, most accountable route for the prescription itself, with in-person oversight, especially if you don't need an app.

Found's real differentiator is breadth and flexibility of medication options at a relatively accessible membership price, plus its AI-and-community support layer. Its disadvantages are the same as the category's: the drug, not the app, does the work; branded-drug coverage is the swing factor on cost; and the compounded pathway trades regulatory protection for price.

The bottom line

Found is a legitimate, venture-backed telehealth weight-care program whose strength is flexibility: licensed clinicians can match you to anything from a cheap generic to a best-in-class branded GLP-1, wrapped in coaching, an AI assistant, and a community. The underlying branded medications it can prescribe — semaglutide (Wegovy) and tirzepatide (Zepbound) — are exceptionally well validated (STEP 1 and SURMOUNT-1, both NEJM), and that is where the real results come from.

But "joining Found" doesn't tell you what treatment you'll actually get, and that ambiguity is the whole decision. If you get a branded GLP-1 covered by insurance, Found can be a sensible, affordable way to access it with support. If you have no coverage, scrutinize the math and the medication: you may end up paying a membership fee plus cash drug prices, or being routed to a compounded, non-FDA-approved product whose safety the FDA has not vetted. Before enrolling, confirm exactly which medication you'll be prescribed and whether it's FDA-approved, get your insurance coverage in writing, read the recurring-billing and cancellation terms, and make sure you have no contraindications to the drug you'll be taking.